| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1541-7786.MCR-07-0324 |
| P698 | PubMed publication ID | 17951399 |
| P2093 | author name string | Paul A Marks | |
| Milos Dokmanovic | |||
| Cathy Clarke | |||
| P433 | issue | 10 | |
| P304 | page(s) | 981-989 | |
| P577 | publication date | 2007-10-01 | |
| P1433 | published in | Molecular Cancer Research | Q2751014 |
| P1476 | title | Histone deacetylase inhibitors: overview and perspectives | |
| P478 | volume | 5 |
| Q30488246 | "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence |
| Q33967429 | 10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells |
| Q51066704 | 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers. |
| Q35680221 | 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? |
| Q38860979 | 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. |
| Q104064745 | A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3 |
| Q57072796 | A Class 1 Histone Deacetylase as Major Regulator of Secondary Metabolite Production in |
| Q92455254 | A Narrative Role of Vitamin D and Its Receptor: With Current Evidence on the Gastric Tissues |
| Q93058752 | A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells |
| Q37040116 | A Role for Nuclear Actin in HDAC 1 and 2 Regulation |
| Q37734520 | A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine |
| Q42590000 | A histone deacetylase-dependent screen in yeast. |
| Q37716435 | A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis |
| Q33940304 | A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold |
| Q33752772 | A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors |
| Q53060196 | A salt bridge turns off the foot-pocket in class-II HDACs. |
| Q53638590 | A steered molecular dynamics mediated hit discovery for histone deacetylases. |
| Q36380832 | A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling |
| Q35417932 | ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy |
| Q46752829 | AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways |
| Q28574090 | Aberrant histone deacetylase2-mediated histone modifications and synaptic plasticity in the amygdala predisposes to anxiety and alcoholism |
| Q36290436 | Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma |
| Q30002375 | Acetylation site specificities of lysine deacetylase inhibitors in human cells |
| Q33567030 | Advances in epigenetic glioblastoma therapy |
| Q47829315 | Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. |
| Q54456214 | Advances in the management of skin cancer. |
| Q42201909 | Alcoholic liver disease - Hepatocellular carcinoma transformation |
| Q26797616 | Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications |
| Q27027924 | Altered histone modifications in gliomas |
| Q57293871 | An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy |
| Q28506446 | An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis |
| Q35747470 | An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. |
| Q49563999 | An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate |
| Q38944047 | An update on the epigenetics of glioblastomas |
| Q40468248 | Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells. |
| Q34257533 | Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor. |
| Q36086326 | Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. |
| Q42050418 | Azalysine analogues as probes for protein lysine deacetylation and demethylation |
| Q37092508 | Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer |
| Q38257914 | Benzotriazole: An overview on its versatile biological behavior |
| Q93376845 | Beta-Hydroxybutyrate Promotes Proliferation, Migration and Stemness in a Subpopulation of 5FU Treated SW480 Cells: Evidence for Metabolic Plasticity in Colon Cancer |
| Q47897379 | Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8. |
| Q37612400 | Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells |
| Q49874330 | Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors |
| Q38916786 | Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents |
| Q33636013 | Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry |
| Q36260249 | Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin |
| Q55449361 | Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells. |
| Q90435510 | Butyrate regulates inflammatory cytokine expression without affecting oxidative respiration in primary astrocytes from spontaneously hypertensive rats |
| Q34384713 | Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells |
| Q36644882 | C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection |
| Q35136778 | CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2. |
| Q42370737 | CRISPR-mediated HDAC2 disruption identifies two distinct classes of target genes in human cells |
| Q26740619 | Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment |
| Q39868674 | Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype |
| Q37825449 | Chemical biology of histone acetyltransferase natural compounds modulators |
| Q33597363 | Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases |
| Q34249695 | Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds |
| Q57012457 | Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress |
| Q38210525 | Chromatin modifications remodel cardiac gene expression |
| Q36707105 | Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression |
| Q48350344 | Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what? |
| Q99637584 | Cleavage of HSP90β induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis |
| Q33443179 | Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat |
| Q38443887 | Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells. |
| Q36994540 | Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model |
| Q33914234 | Combination therapy in combating cancer |
| Q45953663 | Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders. |
| Q30418057 | Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms |
| Q28822124 | Combined Transcriptomics and Chemical-Genetics Reveal Molecular Mode of Action of Valproic acid, an Anticancer Molecule using Budding Yeast Model |
| Q26825040 | Common fragile sites: genomic hotspots of DNA damage and carcinogenesis |
| Q30886620 | Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. |
| Q36742203 | Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells |
| Q58690453 | Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma |
| Q39933597 | Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. |
| Q26860240 | Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future |
| Q36972324 | Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock |
| Q58698929 | Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors |
| Q41986229 | Currying favor for the heart |
| Q39576722 | Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo |
| Q35109281 | Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy |
| Q34752036 | DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation |
| Q95280353 | Design and in silico screening of aryl allyl mercaptan analogs as potential histone deacetylases (HDAC) inhibitors |
| Q35613117 | Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids |
| Q89543118 | Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors |
| Q54279170 | Design, synthesis, and preliminary bioactivity evaluation of N1 -hydroxyterephthalamide derivatives with indole cap as novel histone deacetylase inhibitors. |
| Q38012499 | Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. |
| Q35548131 | Development and validation of a LC-MS assay for the quantification of ikh12 a novel anti-tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study |
| Q37220505 | Differential DNA lesion formation and repair in heterochromatin and euchromatin |
| Q37277291 | Differential cellular and molecular effects of butyrate and trichostatin a on vascular smooth muscle cells |
| Q36469975 | Differential expression of HDAC and HAT genes in atrophying skeletal muscle |
| Q34581227 | Differential patterns of histone acetylation in inflammatory bowel diseases |
| Q48808585 | Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo. |
| Q38534570 | Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. |
| Q54523252 | Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration. |
| Q34718066 | Distinct functional and temporal requirements for zebrafish Hdac1 during neural crest-derived craniofacial and peripheral neuron development |
| Q85092944 | Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery |
| Q39638991 | Does valproic acid induce neuroendocrine differentiation in prostate cancer? |
| Q37288403 | Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas |
| Q35790801 | Drug-set enrichment analysis: a novel tool to investigate drug mode of action |
| Q55337031 | Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. |
| Q35631884 | Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release |
| Q33379343 | Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer |
| Q43247093 | Effect of the histone deacetylase inhibitor trichostatin a on the metabolome of cultured primary hepatocytes |
| Q37086929 | Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. |
| Q93385791 | Effects of a histone deacetylase 3 inhibitor on extinction and reinstatement of cocaine self-administration in rats |
| Q43239274 | Effects of histone deacetylase inhibitors on rat mesangial cells |
| Q38081988 | Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials |
| Q35937982 | Elevated H3K18 acetylation in airway epithelial cells of asthmatic subjects |
| Q37962013 | Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers |
| Q54997679 | Emerging roles for histone deacetylases in age-related muscle atrophy. |
| Q33558093 | Enhanced non-viral gene delivery by coordinated endosomal release and inhibition of β-tubulin deactylase. |
| Q88726264 | Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6 |
| Q38682574 | Environmental toxicants, incidence of degenerative diseases, and therapies from the epigenetic point of view |
| Q50071790 | Epigenetic Activation of Pro-angiogenic Signaling Pathways in Human Endothelial Progenitors Increases Vasculogenesis |
| Q44343064 | Epigenetic Activation of μ-Opioid Receptor Gene via Increased Expression and Function of Mitogen- and Stress-Activated Protein Kinase 1. |
| Q60907794 | Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53 |
| Q37830385 | Epigenetic aberrations during oncogenesis. |
| Q35835175 | Epigenetic activities of flavonoids in the prevention and treatment of cancer |
| Q39220891 | Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment |
| Q37287032 | Epigenetic changes in gliomas |
| Q38472433 | Epigenetic drugs for cancer treatment and prevention: mechanisms of action |
| Q38079160 | Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors |
| Q27024328 | Epigenetic events in liver cancer resulting from alcoholic liver disease |
| Q27023811 | Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities |
| Q28081134 | Epigenetic mechanisms in heart development and disease |
| Q34426222 | Epigenetic mechanisms in schizophrenia. |
| Q37963238 | Epigenetic mechanisms: critical contributors to long-term memory formation |
| Q37905791 | Epigenetic modifications: novel therapeutic strategies for systemic sclerosis? |
| Q38180289 | Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network |
| Q38195005 | Epigenetic molecular recognition: a biomolecular modeling perspective |
| Q38141135 | Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia |
| Q28085420 | Epigenetic regulation of endothelial-cell-mediated vascular repair |
| Q52627695 | Epigenetic regulation of vascular NADPH oxidase expression and reactive oxygen species production by histone deacetylase-dependent mechanisms in experimental diabetes. |
| Q33742171 | Epigenetic remodeling of chromatin architecture: exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas |
| Q26745709 | Epigenetic therapy in gastrointestinal cancer: the right combination |
| Q36885903 | Epigenetic therapy in lung cancer |
| Q27010637 | Epigenetics advancing personalized nanomedicine in cancer therapy |
| Q39358760 | Epigenetics and Liver Fibrosis |
| Q24598045 | Epigenetics of colorectal cancer |
| Q38148588 | Epigenetics of melanoma: implications for immune-based therapies. |
| Q37650610 | Epigenetics of neurological cancers |
| Q37660083 | Epigenome manipulation as a pathway to new natural product scaffolds and their congeners |
| Q34676418 | Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. |
| Q34060558 | Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells |
| Q35329102 | Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter |
| Q35093610 | Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract |
| Q28543059 | Evolutionary constraint and disease associations of post-translational modification sites in human genomes |
| Q35968163 | Experience Modulates the Effects of Histone Deacetylase Inhibitors on Gene and Protein Expression in the Hippocampus: Impaired Plasticity in Aging. |
| Q41981818 | Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells |
| Q37629735 | Extensive functional redundancy in the regulation of Candida albicans drug resistance and morphogenesis by lysine deacetylases Hos2, Hda1, Rpd3 and Rpd31. |
| Q39409895 | Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells |
| Q33950770 | Functional characterization of Candida albicans Hos2 histone deacetylase. |
| Q39177415 | Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells |
| Q50586635 | Functions of miR-1 and miR-133a during the postnatal development of masseter and gastrocnemius muscles. |
| Q36322506 | G9a is essential for epigenetic silencing of K(+) channel genes in acute-to-chronic pain transition. |
| Q37194816 | Genetic dissection of histone deacetylase requirement in tumor cells |
| Q49496829 | Genistein and Trichostatin A Induction of Estrogen Receptor Alpha Gene Expression, Apoptosis and Cell Growth Inhibition in Hepatocellular Carcinoma HepG 2 Cells |
| Q36367583 | Genome-Wide Analysis Reveals Selective Modulation of microRNAs and mRNAs by Histone Deacetylase Inhibitor in B Cells Induced to Undergo Class-Switch DNA Recombination and Plasma Cell Differentiation |
| Q33876916 | Genome-scale analysis of regulatory protein acetylation enzymes from photosynthetic eukaryotes |
| Q35947316 | Glucocorticoid receptor mediated suppression of natural killer cell activity: identification of associated deacetylase and corepressor molecules |
| Q36359485 | HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. |
| Q36471321 | HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components |
| Q48483199 | HDAC Inhibitor Sodium Butyrate-Mediated Epigenetic Regulation Enhances Neuroprotective Function of Microglia During Ischemic Stroke. |
| Q36338516 | HDAC expression and activity is upregulated in diseased lupus-prone mice |
| Q39706886 | HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells |
| Q58572461 | HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth and via inhibiting HDAC8 expression |
| Q64892488 | HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction. |
| Q37514642 | HDAC inhibitor-based therapies and haematological malignancy |
| Q92324516 | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| Q37993586 | HDAC inhibitors for the treatment of cutaneous T-cell lymphomas |
| Q37962336 | HDAC inhibitors in parasitic diseases |
| Q35399130 | HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells |
| Q37674663 | HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy |
| Q37098834 | HDAC1 and HDAC2 in mouse oocytes and preimplantation embryos: Specificity versus compensation |
| Q48283053 | HDAC1 negatively regulates Bdnf and Pvalb required for parvalbumin interneuron maturation in an experience-dependent manner |
| Q24321756 | HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism |
| Q27015801 | HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? |
| Q24310722 | HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation |
| Q37746243 | HDAC8 functions in spindle assembly during mouse oocyte meiosis |
| Q36061902 | HIF2α-Sp1 interaction mediates a deacetylation-dependent FVII-gene activation under hypoxic conditions in ovarian cancer cells |
| Q38755178 | Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions |
| Q26771518 | Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step |
| Q36042059 | Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology |
| Q35195856 | High throughput screening identifies modulators of histone deacetylase inhibitors |
| Q89966140 | Histone Acetylation as a Regenerative Target in the Dentine-Pulp Complex |
| Q40544218 | Histone Deacetylase Gene Expression Following Binge Alcohol Consumption in Rats and Humans. |
| Q64374767 | Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication |
| Q47136872 | Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53. |
| Q39714637 | Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms |
| Q35744910 | Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives |
| Q26783032 | Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy |
| Q34254569 | Histone acetylation in the nucleus accumbens shell modulates ethanol-induced locomotor activity in DBA/2J mice |
| Q36202684 | Histone acetylation regulates prostate ductal morphogenesis through a bone morphogenetic protein-dependent mechanism |
| Q26778780 | Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia |
| Q28082536 | Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy |
| Q41581397 | Histone deacetylase 6 structure and molecular basis of catalysis and inhibition |
| Q36858061 | Histone deacetylase inhibition and dietary short-chain Fatty acids |
| Q37889246 | Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. |
| Q98467280 | Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma |
| Q41033936 | Histone deacetylase inhibition impairs normal intestinal cell proliferation and promotes specific gene expression |
| Q47866992 | Histone deacetylase inhibition, but not a mineralocorticoid receptor antagonist spironolactone, attenuates atypical transcription by an activating mutant MR (MRS 810L ). |
| Q37636118 | Histone deacetylase inhibitor impairs plasminogen activator inhibitor-1 expression via inhibiting TNF-α-activated MAPK/AP-1 signaling cascade. |
| Q34805096 | Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts |
| Q37693855 | Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives |
| Q38595978 | Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies |
| Q58049799 | Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes |
| Q35667942 | Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation |
| Q82233643 | Histone deacetylase inhibitors in cancer therapy |
| Q38212590 | Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience |
| Q37118947 | Histone deacetylase inhibitors in lymphoma and solid malignancies |
| Q38031633 | Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. |
| Q39752287 | Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy |
| Q37169993 | Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms |
| Q45818902 | Histone deacetylase inhibitors suppress immune activation in primary mouse microglia |
| Q36232945 | Histone deacetylase inhibitors through click chemistry |
| Q52699641 | Histone deacetylase inhibitors: Isoform selectivity improves survival in a hemorrhagic shock model. |
| Q24649025 | Histone deacetylase inhibitors: Potential in cancer therapy |
| Q33705588 | Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions |
| Q37595483 | Histone deacetylase inhibitors: current status and overview of recent clinical trials |
| Q37217007 | Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. |
| Q41729088 | Histone deacetylase inhibitory effect of Brazilian propolis and its association with the antitumor effect in Neuro2a cells |
| Q34624058 | Histone deacetylases 9 and 10 are required for homologous recombination |
| Q37621256 | Histone deacetylases and the immunological network: implications in cancer and inflammation |
| Q37974680 | Histone deacetylases and their role in asthma |
| Q57138418 | Histone deacetylases as targets for antitrypanosomal drugs |
| Q38020758 | Histone deacetylases in kidney development: implications for disease and therapy |
| Q37416288 | Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer |
| Q38269737 | Histone-mediated epigenetics in addiction |
| Q39401953 | Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia |
| Q38961023 | Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings |
| Q64096612 | Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays |
| Q36316518 | Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma |
| Q52631343 | Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces. |
| Q91727003 | Immunological Effects of Epigenetic Modifiers |
| Q38428453 | Impact of Epigenetic Dietary Components on Cancer through Histone Modifications |
| Q38529787 | Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer |
| Q39157606 | Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma |
| Q48595586 | In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q41964772 | Inhibition of Class II Histone Deacetylases in the Spinal Cord Attenuates Inflammatory Hyperalgesia |
| Q36926069 | Inhibition of HDAC2 protects the retina from ischemic injury |
| Q38633015 | Inhibition of Histone Methyltransferase, Histone Deacetylase, and β-Catenin Synergistically Enhance the Cardiac Potential of Bone Marrow Cells. |
| Q41440235 | Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model |
| Q41642050 | Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension |
| Q38993736 | Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside |
| Q42835134 | Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells |
| Q38200933 | Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. |
| Q38821833 | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| Q93380136 | Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development |
| Q38726747 | Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients |
| Q37432771 | Investigating the selectivity of metalloenzyme inhibitors |
| Q38561614 | Is miR-34a a Well-equipped Swordsman to Conquer Temple of Molecular Oncology? |
| Q38859450 | Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin |
| Q41850722 | Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a. |
| Q41609801 | LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition |
| Q45943210 | Ligand release mechanisms and channels in histone deacetylases. |
| Q41029112 | Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy |
| Q38972624 | Lithium chloride suppresses LPS-mediated matrix metalloproteinase-9 expression in macrophages through phosphorylation of GSK-3β. |
| Q38791113 | Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model |
| Q37644017 | Long-term culture-induced phenotypic difference and efficient cryopreservation of small intestinal organoids by treatment timing of Rho kinase inhibitor |
| Q41496159 | Loss of histone deacetylase HDAC1 induces cell death in Drosophila epithelial cells through JNK and Hippo signaling |
| Q62663471 | Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile |
| Q48919917 | MS-275, a class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury |
| Q36070523 | Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. |
| Q89174517 | Measuring Histone Deacetylase Inhibition in the Brain |
| Q58038012 | Mechanisms Regulating Transcription inPlasmodium falciparumas Targets for Novel Antimalarial Drugs |
| Q38350489 | Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy |
| Q37592021 | Megabladder mouse model of congenital obstructive nephropathy: genetic etiology and renal adaptation |
| Q38017096 | Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes |
| Q64065815 | Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase |
| Q90669777 | Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes |
| Q34264405 | MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. |
| Q38133765 | Microbial natural products: molecular blueprints for antitumor drugs. |
| Q35656966 | Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole |
| Q26745320 | Modulation of Autophagy by Sorafenib: Effects on Treatment Response |
| Q34635234 | Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock |
| Q37959304 | Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer |
| Q44333090 | Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome. |
| Q28076023 | Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma |
| Q61448703 | Molecular and Functions of the CDK8 and CDK19 Kinase Modules |
| Q34984028 | Molecular basis of renal adaptation in a murine model of congenital obstructive nephropathy |
| Q37644561 | Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies |
| Q37533620 | Molecular epigenetics and genetics in neuro-oncology |
| Q64114104 | Monitoring of chromatin organization in live cells by FRIC. Effects of the inner nuclear membrane protein Samp1 |
| Q36074475 | Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript. |
| Q37979639 | Multiple roles of class I HDACs in proliferation, differentiation, and development |
| Q100529887 | Multitarget inhibition of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K): Current and future prospects |
| Q92674935 | Murine Precision-cut Intestinal Slices as a Potential Screening Tool for Antifibrotic Drugs |
| Q52565514 | Mutual inhibition between HDAC9 and miR-17 regulates osteogenesis of human periodontal ligament stem cells in inflammatory conditions. |
| Q38938284 | Mycobacterium tuberculosis Infection Induces HDAC1-Mediated Suppression of IL-12B Gene Expression in Macrophages |
| Q40965816 | Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells. |
| Q48181021 | New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death |
| Q37503780 | New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer |
| Q27004421 | New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) |
| Q34380256 | New perspectives of valproic acid in clinical practice. |
| Q47097443 | Nicorandil potentiates sodium butyrate induced preconditioning of neurons and enhances their survival upon subsequent treatment with H2O2. |
| Q48379148 | Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat |
| Q33635942 | Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases |
| Q28067375 | Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site |
| Q38261677 | Novel agents and new therapeutic approaches for treatment of multiple myeloma. |
| Q52926182 | Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. |
| Q34145992 | Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells |
| Q58689803 | Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors |
| Q37272145 | P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. |
| Q34703660 | PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma |
| Q34199935 | PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo |
| Q28388468 | PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy |
| Q92310282 | PROTACs: great opportunities for academia and industry |
| Q48219950 | PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors |
| Q93080138 | Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau |
| Q42920116 | Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists |
| Q38835113 | Panobinostat for the treatment of acute myelogenous leukemia |
| Q42081115 | Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells |
| Q37150016 | Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma |
| Q37520649 | Phase I study of pemetrexed with sorafenib in advanced solid tumors |
| Q40351982 | Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. |
| Q33391851 | Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study |
| Q36270038 | Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay |
| Q60328228 | Platinum(IV) Prodrugs - A Step Closer to Ehrlich's Vision? |
| Q47621039 | Poly(N-(2-Hydroxypropyl) Methacrylamide)-Valproic Acid Conjugates as Block Copolymer Nanocarriers |
| Q35336915 | Polycomb-mediated silencing in neuroendocrine prostate cancer. |
| Q33768549 | Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors |
| Q49131145 | Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A. |
| Q35485587 | Potential non-oncological applications of histone deacetylase inhibitors |
| Q38041123 | Potential of chromatin modifying compounds for the treatment of Alzheimer's disease |
| Q30459589 | Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas |
| Q90669799 | Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes |
| Q39047967 | Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. |
| Q28487129 | Quantitative analysis of histone modifications: formaldehyde is a source of pathological n(6)-formyllysine that is refractory to histone deacetylases |
| Q37992086 | Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010). |
| Q91722649 | RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells |
| Q39166818 | RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. |
| Q98394726 | RUNX2-modifying enzymes: therapeutic targets for bone diseases |
| Q34044049 | Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A |
| Q37446333 | Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: a new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systems |
| Q52596812 | Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. |
| Q52391083 | Recent Advances in the Synthesis of Peptoid Macrocycles. |
| Q38539386 | Recent advances in targeted therapy for glioblastoma |
| Q36646486 | Redox control of leukemia: from molecular mechanisms to therapeutic opportunities |
| Q33825179 | Redundant control of adipogenesis by histone deacetylases 1 and 2 |
| Q45814092 | Regional and cell-type specific distribution of HDAC2 in the adult mouse brain |
| Q64063293 | Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases |
| Q36574016 | Regulation of Histone Acetylation by Autophagy in Parkinson Disease |
| Q37598556 | Regulation of genes related to immune signaling and detoxification in Apis mellifera by an inhibitor of histone deacetylation |
| Q33773569 | Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. |
| Q48034366 | Regulation of the Glycerol Transporter, Aquaporin-3, by Histone Deacetylase-3 and p53 in Keratinocytes. |
| Q36995044 | Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors |
| Q38041728 | Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations. |
| Q36236921 | Respiratory syncytial virus infection down-regulates antioxidant enzyme expression by triggering deacetylation-proteasomal degradation of Nrf2. |
| Q41065604 | Restoring histone deacetylase activity by waste product release. A view from molecular mechanics simulations with mammalian HDAC8. |
| Q35688315 | Retinoic Acid Induces Embryonic Stem Cell Differentiation by Altering Both Encoding RNA and microRNA Expression |
| Q36605917 | Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma |
| Q48163960 | Reverse Biosynthesis: Generating Combinatorial Pools of Drug Leads from Enzyme-Mediated Fragmentation of Natural Products |
| Q33167710 | Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial |
| Q37445508 | Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells |
| Q37199772 | Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat |
| Q36982745 | Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions |
| Q47951320 | Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice |
| Q33390876 | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. |
| Q27312323 | SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease |
| Q38421269 | SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin |
| Q48293164 | SCFAs strongly stimulate PYY production in human enteroendocrine cells. |
| Q38186171 | SIRT1 in neurodevelopment and brain senescence |
| Q90669066 | Seeking Convergence and Cure with New Myeloma Therapies |
| Q38246144 | Selective class IIa HDAC inhibitors: myth or reality |
| Q34482017 | Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB |
| Q34358718 | Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents |
| Q39653684 | Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells |
| Q36798069 | Single-cell microarray enables high-throughput evaluation of DNA double-strand breaks and DNA repair inhibitors |
| Q38108128 | Sirtuin deacetylases in neurodegenerative diseases of aging |
| Q39433077 | Sirtuins in Skin and Skin Cancers |
| Q37671589 | Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. |
| Q33615259 | Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest |
| Q41635922 | Sodium butyrate has context-dependent actions on dipeptidyl peptidase-4 and other metabolic parameters. |
| Q45732414 | Sodium butyrate potentiates carbon tetrachloride-induced acute liver injury in mice |
| Q28564318 | Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. |
| Q27025501 | Stress, epigenetics, and alcoholism |
| Q42064958 | Structure based design, synthesis and activity studies of small hybrid molecules as HDAC and G9a dual inhibitors |
| Q47422106 | Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors. |
| Q33570972 | Studies on the antiproliferative effects of tropolone derivatives in Jurkat T-lymphocyte cells |
| Q39775243 | Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. |
| Q34629026 | Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells |
| Q37423898 | Suberoylanilide hydroxamic acid represses glioma stem-like cells. |
| Q35232590 | Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line |
| Q35708210 | Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage |
| Q39690963 | Surviving lethal septic shock without fluid resuscitation in a rodent model |
| Q37680216 | Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo |
| Q94465671 | Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group |
| Q35637328 | Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors |
| Q37271928 | Systemic cancer therapy: evolution over the last 60 years |
| Q48666421 | Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes. |
| Q58042312 | TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells |
| Q36685194 | TAp73 protein stability is controlled by histone deacetylase 1 via regulation of Hsp90 chaperone function |
| Q88509535 | TRPV4-Mediated Anti-nociceptive Effect of Suberanilohydroxamic Acid on Mechanical Pain |
| Q47599592 | Targeted Gene Repression Using Novel Bifunctional Molecules to Harness Endogenous Histone Deacetylation Activity. |
| Q90398519 | Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin |
| Q28548415 | Targeting Lysine Deacetylases (KDACs) in Parasites |
| Q37662400 | Targeting binding partners of the CBFβ-SMMHC fusion protein for the treatment of inversion 16 acute myeloid leukemia |
| Q38159805 | Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies |
| Q93139190 | Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics |
| Q37317000 | Targeting important pathways in head and neck cancer: from the bench to the clinic |
| Q49544302 | Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer |
| Q36245380 | Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat |
| Q37620996 | The Brm-HDAC3-Erm repressor complex suppresses dedifferentiation in Drosophila type II neuroblast lineages |
| Q41181386 | The Co-Expression Pattern of p63 and HDAC1: A Potential Way to Disclose Stem Cells in Interfollicular Epidermis |
| Q34414447 | The DAC system and associations with multiple myeloma. |
| Q39174018 | The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner |
| Q33934350 | The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression |
| Q64277594 | The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model |
| Q40961675 | The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava. |
| Q35899944 | The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor β Signaling |
| Q60958597 | The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus |
| Q47765177 | The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments |
| Q26771271 | The Prodrug Approach: A Successful Tool for Improving Drug Solubility |
| Q38341929 | The Role of HDACs as Leukemia Therapy Targets using HDI. |
| Q97093976 | The Role of Histone Acetyltransferases and Histone Deacetylases in Photoreceptor Differentiation and Degeneration |
| Q36984494 | The aggresome pathway as a target for therapy in hematologic malignancies |
| Q33829390 | The clinical development of histone deacetylase inhibitors as targeted anticancer drugs |
| Q45335806 | The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors. |
| Q38095611 | The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers |
| Q42022435 | The epigenetic modifiers 5-aza-2'-deoxycytidine and trichostatin A influence adipocyte differentiation in human mesenchymal stem cells |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q52679783 | The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis. |
| Q42365518 | The expression of histone deacetylases and the regenerative abilities of spinal-projecting neurons after injury |
| Q38749473 | The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines |
| Q36850449 | The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression |
| Q34771550 | The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells |
| Q42207197 | The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. |
| Q43970077 | The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells |
| Q37477372 | The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta |
| Q30580509 | The mutational landscape of chromatin regulatory factors across 4,623 tumor samples |
| Q38697860 | The nature of the GRE influences the screening for GR-activity enhancing modulators. |
| Q28087539 | The promise and perils of HDAC inhibitors in neurodegeneration |
| Q49964101 | The protein acyltransferase Pat post-transcriptionally controls HilD to repress Salmonella invasion |
| Q33660253 | The quality control theory of aging |
| Q38260795 | The role of dietary histone deacetylases (HDACs) inhibitors in health and disease |
| Q34279114 | The role of histone acetylation in memory formation and cognitive impairments |
| Q38826161 | The role of post-translational modifications in hearing and deafness |
| Q52680326 | The role of zinc and its compounds in leukemia. |
| Q39790087 | The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair |
| Q35133494 | The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. |
| Q36001865 | The transposon-driven evolutionary origin and basis of histone deacetylase functions and limitations in disease prevention |
| Q64255334 | The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets |
| Q26746231 | The world of protein acetylation |
| Q26782916 | Therapeutic Approaches to Histone Reprogramming in Retinal Degeneration |
| Q39236500 | Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma |
| Q27016002 | Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma |
| Q53080989 | Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice. |
| Q42658762 | Transcriptional regulation of Nox4 by histone deacetylases in human endothelial cells. |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
| Q34361211 | Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. |
| Q47445768 | Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity |
| Q54256508 | Trichostatin A inhibits the activation of Hepatic stellate cells by Increasing C/EBP-α Acetylation in vivo and in vitro. |
| Q35001758 | Triple-negative breast cancer: new perspectives for targeted therapies. |
| Q33754921 | Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis |
| Q91717473 | Tumour Expression of Histone Deacetylases in Uveal Melanoma |
| Q34137377 | Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases |
| Q35374953 | Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression |
| Q47332332 | Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors |
| Q34607095 | Use of epigenetic drugs in disease: an overview |
| Q38696371 | Valproate increases dopamine transporter expression through histone acetylation and enhanced promoter binding of Nurr1. |
| Q36509087 | Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs |
| Q88737586 | Valproic acid attenuates manganese-induced reduction in expression of GLT-1 and GLAST with concomitant changes in murine dopaminergic neurotoxicity |
| Q64389971 | Valproic acid causes radiosensitivity of breast cancer cells disrupting the DNA repair pathway |
| Q33994818 | Vascular histone deacetylation by pharmacological HDAC inhibition |
| Q35477216 | Virtual screening in small molecule discovery for epigenetic targets. |
| Q34632964 | Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study |
| Q34048411 | Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...] |
| Q33432199 | Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis |
| Q41347745 | Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. |
| Q28583893 | Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes |
| Q37073274 | ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells |
| Q51742940 | miR-2861 as novel HDAC5 inhibitor in CHO cells enhances productivity while maintaining product quality. |
| Q92083193 | p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death |
| Q52645040 | p53-Mediated Molecular Control of Autophagy in Tumor Cells. |
Search more.